Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04174170 · ClinicalTrials.gov registry record · Phase 3
Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 591
- Enrollment target
NCT04174170 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 591 participants.
The verdict
NCT04174170, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 591 participants
- Enrollment target
Study Summary
This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of fixed-dose brexpiprazole + sertraline combination treatment in adult subjects with post-traumatic stress disorder.
Interventions
- OTHER Placebo
- DRUG Sertraline
- DRUG Brexpiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 591 participants |
| Start Date | 2019-10-30 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04174170
The ClinicalTrials.gov registry entry for NCT04174170 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 591 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04174170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04174170 about?
NCT04174170 is a clinical study titled "Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder". This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of fixed-dose brexpiprazole + sertraline combination treatment in adult subjects with post-traumatic stress disorder.
What is the current status of trial NCT04174170?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 591 participants. The study started on 2019-10-30. Estimated completion is 2023-08-15.
What interventions are being tested in trial NCT04174170?
The interventions under investigation include: Placebo (OTHER), Sertraline (DRUG), Brexpiprazole (DRUG).
Who is sponsoring clinical trial NCT04174170?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.